<DOC>
	<DOCNO>NCT02538978</DOCNO>
	<brief_summary>This prospective , double-blinded , randomize , placebo-controlled , multi-center , pivotal clinical study subject evaluate prevention major limb amputation treatment non-reconstructable Rutherford Category 5 critical limb ischemia ( CLI ) . Subjects randomized 3:1 ratio ( device treatment : placebo-control ) .</brief_summary>
	<brief_title>Critical Limb Ischemia Rapid Delivery SurgWerks-CLI Kit VXP System</brief_title>
	<detailed_description>Device arm subject receive intra-operative point care aspiration , preparation intramuscular injection autologous bone marrow cell concentrate ( aBMC ) afflict low index limb . Bone marrow collect bilaterally patient 's iliac crest use SurgWerks-CLI Kit aspiration trocar local anesthesia mild moderate sedation general anesthesia , process VXP System device yield rich cell plasma concentrate ( `` aBMC '' ) . Additionally , 10 mL autologous peripheral blood aspirate placebo preparation . The Treatment Arm receive aBMC , intramuscularly inject multiple map sites/angiosomes ischemic index limb use SurgWerks-CLI Kit supply Therapeutic Infusion Needles standard hypodermic needle . The procedure perform surgical suite take approximately 1.5-2.0 hour complete . The subject observe 24 hour follow procedure observation control necessary post-operative pain , bleeding , infection . Placebo Arm subject undergo intra-operative point care aspiration preparation bone marrow via investigational device exactly Treatment Arm . However , instead receive dose aBMC device output , receive intramuscular injection dilute autologous peripheral blood afflict low index limb . At pre-specified follow-up interval , subject arm evaluate : - Major limb amputation free survival - Time Treatment Failure ( TTF ) - Wound healing : Quantitative evaluation wound ( ) - Quality life assessment ( VascuQoL SF-36 ) - Skin Perfusion Pressure ( SPP ) - Quantitative evaluation blood flow - Rest pain assessment - Brachial Index ( ABI )</detailed_description>
	<mesh_term>Ischemia</mesh_term>
	<criteria>Inclusion Criteria IC 1 Male Female age ≥ 40 ≤ 85 year . IC 2 Chronic CLI atherosclerotic ischemic peripheral arterial disease ( PAD ) low limb classify Rutherford Category 5 : ( ischemic pain rest minor tissue loss ulceration per IC 3 ) . IC 3 Ulcer toe ( ) and/or foot ( ankle ) total tissue loss ( full thickness ) least 0.5 cm2 great 20 cm2 ( 0.5 cm2 ≤ wound area ≤ 20 cm2 ) great 10 cm2 heel . Note : expose tendon bone exclusion , see EC 7 IC 4 A nonsurgical candidate revascularization rule investigator confirm BICR ( single reader ) define : failure previous standard revascularization therapy /reconstruction attempt ( least two week prior enrollment ) conduit suitable bypass grafting , medical high risk precludes bypass surgery , diffuse multisegment disease , extensive infrapopliteal disease amenable endovascular therapy.. IC 5 Ability maintain compliance tolerate medical management regimen PAD include smoke cessation , may include management hyperlipidemia , diabetic management , antiplatelet therapy , statin therapy , ACE inhibitor therapy ( ARB therapy ) beta blocker therapy control blood pressure . IC 6 Willingness , ability commitment participate baseline followup evaluation full length study . IC 7 Poor low extremity perfusion define : ABI ≤ 0.6 , Foot/Ankle SPP ≤ 30 mmHg , Ankle systolic pressure ≤ 60 mmHg Toe pressure &lt; 40 mmHg IC 8 Written informed consent . Exclusion Criteria EC1 Women pregnant , lactate plan pregnancy twelve ( 12 ) month followup period . EC2 Advanced CLI affect index limb classify category Rutherford 5 . EC3 Advanced CLI oppose limb ( nonindex ) Rutherford category 6 . EC4 Patients aortailiac occlusive disease &gt; 50 % stenosis EC5 Any prior amputation index limb beyond toe ( ) digits transmetatarsal past four week . EC6 Ischemic wound systemic infectious symptom ( fever , hypotension , and/or positive blood culture ) . EC7 Ischemic wound expose tendon bone . EC8 PT/INR &gt; 2.0 preadmission baseline . If warfarin , PT/INR titrate ≥ 2.0 prior treatment procedure . EC9 Ulcers ankle EC10 Subjects renal dialysis end stage renal disease ( Serum creatinine ≥ 2.5 mg/dl GFR ≤ 15 use CKDEPI equation National Kidney Foundation ) . EC11 Poorly control diabetes mellitus ( HbA1c ≥ 10 % ) EC12 Anemia define Hgb ≤ 10mg/dl HCT ≤ 30 % EC13 Any diagnose immunedeficient status except wellcontrolled HIV infection ( define HIV RNA qPCR ≤ 20 copies/mL ) . EC14 History neoplastic disease/cancer ( basal cell carcinoma ) previous three ( 3 ) year . EC15 Intolerance heparin . EC16 Contraindicated CT angiography . EC17 Medical risk precludes anesthesia , ASA Class 5 EC18 Receiving antiangiogenic treatment EC19 History coronary revascularization within previous one ( 1 ) month . EC20 History stroke within previous six ( 6 ) month . EC21 Anticipated need immunosuppressive drug ( include glucocorticoid ) . EC22 Subjects severe nonproliferative proliferative retinopathy . EC23 Patients active know alcohol illicit drug abuse . EC24 Severe comorbidity ( i.e . cardiac pulmonary ) poor general physical/mental health , opinion Investigator , allow subject suitable study candidate ( i.e . advanced disease process , diminish mental capacity , substance abuse , shorten life expectancy ( ≤1 year ) , etc. ) . EC25 The patient currently involve another clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>CLI</keyword>
</DOC>